Potential impact of Paracentrotus lividus extract on diabetic rat models induced by high fat diet/streptozotocin  by Soliman, Amel M.
The Journal of Basic & Applied Zoology (2016) 77, 8–20HO ST E D  BY
The Egyptian German Society for Zoology
The Journal of Basic & Applied Zoology
www.egsz.org
www.sciencedirect.comPotential impact of Paracentrotus lividus extract
on diabetic rat models induced by high fat
diet/streptozotocinPeer review under responsibility of The Egyptian German Society for
Zoology.
http://dx.doi.org/10.1016/j.jobaz.2016.01.001
2090-9896  2016 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V.







Oxidative stressAbstract Antioxidant therapy has been thought to be effectual for the prevention and treatment of
various diseases including diabetes. Therefore, the present study was designed to investigate the
potency of Paracentrotus lividus extract (PLE) for alleviating the complications that resulted after
induction of the diabetic rat models (T1DM and T2DM) using high fat diet (HFD)/streptozotocin
(STZ). Thirty six male Wistar albino rats were assigned into normal control, T1DM and T2DM
untreated, and PLE treated diabetic rat groups. Induction of T1DM was performed by streptozo-
tocin injection (60 mg/kg of dissolved in sodium citrate buffer, 0.1 mol/L, i.p). T2DM induction
through 4 weeks of high fat diet (HFD) intervention was followed by a single low dosage of STZ
(30 mg/kg dissolved in 0.1 mol/L citrate buffer at pH 4.5, i.p). Both diabetic rat models showed
a significant increase in serum; levels of fasting glucose, total protein, bilirubin, activities of argi-
nase, transaminases (AST and ALT), alkaline phosphatase (ALP), c glutamyl transferase (GGT),
lipid profile parameters, and liver malondialdehyde (MDA). However, T1DM and T2DM rats have
decreased levels of serum insulin, and liver glucose 6 phosphate dehydrogenase (G6PD), glutathione
reduced (GSH), nitric oxide (NO), and antioxidant enzymes. Furthermore, the present study
showed the hypoglycemic, hypolipidemic, and antioxidant potency of the PLE as confirmed by
its ability for ameliorating most of the alterations caused in the studied parameters of diabetic rats.
In conclusion, PLE may be useful as therapy against oxidative stress and liver damage in both types
of diabetes mellitus and is therefore recommended for further studies.
 2016 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetes is really a devastating epidemic of the 21st century
and is becoming the third killer of the health of human beings
after cancer, cerebrovascular and cardiovascular diseases. Notonly it takes a heavy toll of lives around the world but imposes
a serious financial burden on the sufferers and their family
members (Bhattacharjee et al., 2014). Diabetes mellitus (DM)
is a common metabolic disease with many side effects (Ziaee
et al., 2013; Pang et al., 2015). Diabetes is characterized by
hyperglycemia resulting in insulin resistance and/or insulin sec-
ondary deficiency caused by the failure of beta- (b-) pancreatic
cells (Damasceno et al., 2014). Diabetes caused impaired
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Several experimental models of type 1 and type 2 diabetes are
available in rats (Fuentes-Antra´s et al., 2015). Type 1 diabetes
mellitus (T1DM) is one of the most prevalent autoimmune dis-
eases in the western world (van den Brandt et al., 2010). Type 1
diabetic patients often present acute symptoms of diabetes and
markedly increased glucose levels and in some cases ketoacido-
sis appears (Damasceno et al., 2014). On the other hand, type 2
diabetes mellitus (T2DM) is characterized by reduced pancre-
atic beta-cell function and systemic insulin resistance, leading
to metabolic dysfunction throughout the body (Onur et al.,
2014). The beta cells normally compensate insulin resistance
by secreting larger amounts of insulin to maintain the glucose
homeostasis (Riguera, 1997). In the course of time, however,
this beta cell function gets impaired leading to deterioration
in glucose homeostasis and subsequent development of
impaired glucose tolerance and frank diabetes (Lebovitz and
Banerji, 2004). Type 2 diabetes is frequently not diagnosed until
complications appear (Damasceno et al., 2014).
Streptozotocin (STZ) is an antibiotic produced by Strepto-
myces achromogenes and is also used as an FDA-approved
drug in the metastatic cancer of pancreatic islets cells
(Kahraman et al., 2015). It inhibits glucose oxidation and
glucose-induced insulin secretion in beta cells via nitric oxide
production, alkylation, and DNA fragmentation (Lenzen,
2008). STZ leads to kidney and liver toxicity as well as beta cell
damage (Dufrane et al., 2006). STZ is widely used in studies of
experimental type-1 diabetes because it selectively destroys
pancreatic b cells through the generation of ROS and alkyla-
tion of deoxyribonucleic acid (DNA) (Lenzen, 2008). The
use of fat-fed/STZ-treated rat models imitates natural disease
incidence and metabolic characteristics typical of persons at
increased risk of type 2 diabetes because of both insulin resis-
tance and obesity (Srinivasan et al., 2005).
Liver as the major target organ of insulin plays important
roles in the development of insulin resistance and type 2 dia-
betes mellitus, and the underlying mechanisms are still not
fully understood (Leng et al., 2014). Previous clinical studies
documented liver disease as a major cause of mortality in
patients with DM (Clouston and Powell, 2004; Jin et al.,
2005). The scope of liver disease in DM includes the non-
alcoholic fatty liver disease (NAFLD), characterized by fat
accumulation in hepatocytes. Conditions like hypertriglyc-
eridemia and hypercholesterolemia are described as a cause
of NAFLD (Al-Jameil et al., 2014). Several organizations, rec-
ommend that lifestyle modifications, such as nutrition therapy,
has been shown to help some patients to achieve better lipid
levels (Jaiswal et al., 2014). In addition, hyperglycemia in dia-
betic patients is associated with alteration in glucose and lipid
metabolism and modification in liver enzyme levels (Jenson
et al., 1998).
Hyperglycemia has been identified as a major cause for
reactive oxygen species (ROS) generation (Forbes et al.,
2008). Oxidative stress is currently suggested as the mechanism
underlying diabetes and diabetic complications (Cade, 2008;
Lupachyk et al., 2013). Oxidative stress results from an imbal-
ance between radical generating and radical scavenging mech-
anisms i.e. increased free radical production or abridged
activity of antioxidant defenses or both (Ahmed et al., 2014).
Szkudelski (2001) reported that oxidative stress is increased
in experimental models of streptozotocin (STZ)-induced dia-
betes mellitus in rats. DM impaired glutathione metabolism,and caused alterations in the antioxidant enzymes and genera-
tion of lipid peroxides (McLennan et al., 1991; Strain, 1991).
Increased oxidative stress has been implicated in the etiol-
ogy (especially type 1) and pathology (both type 1 and type
2) of diabetic complications (Robertson and Harmon, 2006;
Rolo and Palmeira, 2006). Pancreatic beta cells exposed to
hyperglycemia and reactive oxygen species displayed reduced
insulin secretion and increased insulin resistance (Sakai et al.,
2003). It is therefore suggested that suppression of oxidative
stress in beta cells may prevent or delay the onset of type 1
and progression of type 2 diabetes and related complications.
Several studies have also shown that treatment with antioxi-
dants protects against the onset of diabetes (Kaneto et al.,
1999; Yu et al., 2006).
The handling of this disorder requires increased physical
activity, healthy eating or diet and administration of anti-
diabetic drugs and/or insulin. However, the currently available
anti-diabetic drugs are far from being satisfactory. This may
partly be attributed to the fact that diabetes is a disorder with
multifactorial and heterogeneous etiologies (Erejuwa, 2014).
Besides, these agents are costly and, in some cases, not readily
available. Although several synthetic hypoglycemics are devel-
oped the safe and effective treatment paradigm is yet to be
developed (Bhattacharjee et al., 2014). Therefore, a large per-
centage of the populations are resorting to complementary
and alternative medicine (CAM) (Nahas and Moher, 2009).
Insulin replacement therapy is the mainstay of treatment in
patients with type 1 diabetes while type 2 diabetes should be
regarded as a potentially preventable disease (Bastaki, 2005).
Consequently, antioxidant therapy has been thought to be
effectual for the prevention and treatment of various diseases
including diabetes, because oxidative stress plays a key role
in the pathogenesis of human diseases (Medina and Moreno-
Otero, 2005).
In recent years, great attention has been paid to study the
bioactivity of natural products due to their potential pharma-
cological utilization. However, majority of marine organisms
are yet to be screened for discovering useful antibiotics
(Bragadeeswaran et al., 2013). Marine organisms represent
an excellent source for bioactive compounds (Bickmeyer
et al., 2005) and modern technologies have opened vast areas
of research for the extraction of biomedical compounds from
ocean and seas to treat the deadly diseases (Bragadeeswaran
et al., 2013).
Sea urchins are spiny-skinned marine invertebrates with a
global distribution (Chung, 2013). It has shown that the use
of sea urchin shells confers certain beneficial advantages,
including antioxidant and pharmaceutical effects (Kim et al.,
2002; Shankarlal et al., 2011). In sea urchin gonads polyhy-
doxylated naphthoquinone, echinochrome A, of which potent
antioxidant activity has been reported (Lebedev et al., 2001). It
was reported that 3-sulfonoquinovosyl-1-monoacylglycerol
extracted from sea urchin intestine was effective in suppressing
the growth of solid tumors (Sahara et al., 1997). There are
much valuable information for new antibiotic discoveries
and give new insights into bioactive compounds in sea urchin
(Bragadeeswaran et al., 2013). Sea urchins have therefore
received increased attention as a possible source of antibiotic
replacements (Chung, 2013).
It was proposed here that the hyperglycemia-induced acti-
vation of stress pathways plays a key role in the development
of not only the late complications in type 1 and type 2 diabetes,
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seen in type 2 diabetes. Therefore, the present study aims to
evaluate the hypoglycemic, hypolipidemic and antioxidant
effects of the sea urchin (Paracentrotus lividus) soft body
methanolic extract on T1DM and T2DM rat models.
Materials and methods
Chemicals and reagents
Streptozotocin, dimethyl sulfoxide (DMSO) and insulin kits
were purchased from Sigma–Aldrich (St. Louis, MO, USA).
Kits for most of the biochemical analysis determinations were
purchased from the Biodiagnostic Company (Dokki, Giza,
Egypt). The kit for c-glutamyl transferase analysis was pur-
chased from Spectrum Company (Obour City, Cairo, Egypt).
Sea urchins collection
Sea urchins (P. lividus) were collected from the Mediterranean
Coast of Alexandria (Egypt) and transported to the laboratory
packed in ice. The samples were thoroughly washed with sea
water to remove sand and overgrowing organisms at the col-
lection site and transported to the laboratory. The collected
specimens identified by the standard literature of taxonomic
guide by Clark and Rowe (1971).
Preparation of the P. lividus extracts (PLE)
The sea urchins soft body parts (Gonads, mouth part and gut)
were pooled and washed with a stream of cold water, air-dried
at 4 C for 2 days in the dark and then ground. The samples
were then stored in the dark at room temperature to avoid
photolysis and thermo-degradation of secondary metabolites
prior to extraction. Samples (4 g) were homogenized and
extracted with 10 volumes (v/w) of 70% (v/v) methanol. The
supernatant for each sample was collected by centrifugation
(12,000g, 5 min, and 4 C) and stored at 20 C. The super-
natant of each extract was then filtered through a 0.2 lm Mil-
lipore filter (Nalge, Rochester, NY, USA).The filtrate was
collected immediately, concentrated and lyophilized using lyo-
philizer (LABCONCO lyophilizer, shell freeze system, USA).
Experimental animals
The experimental animals used in this study were male Wistar
rats (Rattus norvegicus) weighing 150–160 ± 5 g. The animals
were obtained from the National Research Center (NRC,
Dokki, Giza). Animals were grouped and housed in polyacrylic
cages in the well – ventilated animal house of the Zoology
Department, Faculty of Science, Cairo University. Animals
were given food and water ad libitum. Rats were maintained in
a friendly environment of a 12-h/12-h light–dark cycle at room
temperature (22–25 C). Rats were acclimatized to laboratory
conditions for 7 days before commencement of the experiment.
Acute oral toxicity study
Acute toxicity studies were performed according to the
Organization of Economic Cooperation and Development(OECD) guideline 425 (OECD, 2001). Ten healthy male
albino rats, fasted overnight, were divided into two groups
with five animals in each group. The first group received dis-
tilled water and served as control. The second group was
administered methanol extract of P. lividus (PLE) in suspen-
sion at a limit test dosage of 5000 mg/kg body weight. All
doses were administered by gastric gavage, and each dose
was adjusted to be 2 ml/kg. The animals were observed post
dose at 0 min, 30 min, 1 h, 2 h, 4 h, 6 h, and thereafter every
day for 14 days.Induction of type 1 diabetes
All animals were starved for 12 h before the experiment, but
were allowed free access to water. Diabetes was induced by
intraperitoneal injection of streptozotocin (60 mg/kg dissolved
in sodium citrate buffer, 0.1 mol/L). Blood glucose levels were
measured 72 h after injection of STZ. Animals were starved,
but had access to drinking water for 6 h before blood glucose
measurement. Plasma glucose concentrationsP300 mg/100 ml
were considered diabetic type 1 in this experiment (Chen et al.,
2014).
Induction of type 2 diabetes
Following 4 weeks of high fat diet (HFD) (with energy of
5.3 kcal/g, comprising 60% calories from fat, 35% from pro-
tein and 5% from carbohydrate) intervention (Reed et al.,
2000), the rats were injected intraperitoneally by a single
dose of prepared solution of STZ (30 mg/kg suspended in
0.1 mol/L citrate buffer at pH 4.5). If the fasting blood glu-
cose (FBG) was more than 300 mg/100 ml after 72 h of STZ
injection, the diabetic type 2 model was successful (Ebaid,
2014).
Experimental design
After one week of acclimatization, Thirty six male Wistar
albino rats were assigned into two main experiments:
A. Experiment I (T1DM): Eighteen rats were divided into 2
groupsGroup 1: Served as normal control (NC). Six rats
received 1 ml (10% DMSO, orally) daily for 15 days
after a single dose of citrate buffer (0.1 mol/L, i.p).
Group 2: Twelve rats were used for T1DM induction.
Then six diabetic rats received 1 ml (10% DMSO,
orally) (DC), and the rest of rats received 1 ml PLE dis-
solved 10% DMSO (500 mg/kg body weight, orally),
daily for 15 days.
B. Experiment II (T2DM): Eighteen rats were divided into
2 groups
Group 1: Rats (6 rats) consumed a regular diet without
STZ injection. After 4 weeks of normal diets, it received
1 ml (10% DMSO, orally) daily for 15 days after a single
dose of citrate buffer (0.1 mol/L, i.p) (NC).
Groups 2: Twelve rats were used for T2DM induction.
Half of the diabetic rats received 1 ml (10% DMSO,
orally) (DC), and the others received 1 ml of PLE
(500 mg/kg body weight, orally), daily for 15 days.
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At the end of each experiment, the fasted rats were euthanized
after being anesthetized with 3% sodium pentobarbital and the
chest was opened. A needle was inserted through the dia-
phragm and into the heart. Negative pressure was gently
applied once the heart had been punctured, and the needle
was repositioned as required until blood flowed into the syr-
inge. Blood samples were collected in centrifuge tubes for bio-
chemical analysis. Liver and pancreas samples were quickly
removed washed with physiological saline to remove traces




Blood samples were collected in centrifuge tubes without anti-
coagulant, allowed to clot, and centrifuged at 3000 rpm/min
for 20 min. The serum obtained was stored at 20 C until
used for biochemical assays.
Liver tissue homogenate preparation
Liver tissue was homogenized (10% w/v) using a Potter Elve-
hjem homogenizer (Sigma Aldrich) in ice-cold 0.1 M Tris–HCl
buffers (pH 7.4). The homogenate was centrifuged at 860g
for 15 min. at 4 C, and the resultant supernatant was used
for different assays.
Biochemical assays
Serum glucose was determined according to Trinder (1969)
method, serum arginase (Marsch, 1965), serum insulin
(Herbert et al., 1965), aminotransferase enzyme activities (ala-
nine transaminase (ALT) and aspartate transaminase (AST))
(Reitman and Frankel, 1957), alkaline phosphatase (ALP)
activity (Belfield and Goldberg, 1971), c-glutamyl transferase
(GGT) activity (Szasz, 1974), total protein (Henry, 1964), total
and direct bilirubin levels (Walter and Gerade, 1970), total
lipids ((Knight et al., 1972), triglycerides (Fossati and
Prencipe, 1982), total cholesterol (Allain et al., 1974), high den-
sity lipoprotein (HDL) level (Lopez-Virella et al., 1977), and
low density lipoprotein (LDH) level (Wieland and Seidel,
1983), liver glucose 6 phosphate dehydrogenase (G6PD)
(Kornberg and Horecker, 1955), liver lipid peroxidation
(LPO), which was measured by the formation of malondialde-
hyde (MDA) (Ohkawa et al., 1979), liver reduced glutathione
(GSH) (Aykac et al., 1985), liver nitric oxide (NO)
(Montgomery and Dymock, 1961), liver glutathione-S-
transferase (GST) (Habig et al., 1974), liver glutathione perox-
idase (GPx) (Paglia and Valentine, 1967), liver superoxide
dismutase (SOD) (Nishikimi et al., 1972), and liver catalase
(CAT) (Aebi, 1984).
Statistical analysis
Results were expressed as mean ± standard error% improve-
ment = treated mean  model mean/control mean  100%.
All data obtained were analyzed by analysis of variance,
followed by Student’s t test at 95% confidence level. Values
of p< 0.05 were considered as statistically significant. Allcomputations were performed using Statistical Package for
Social Sciences version 15.0 software.
Results
Acute oral toxicity test
Single oral administration of P. lividus extract (PLE)
(5000 mg/kg body weight) did not show any visible signs of
toxicity, abnormal behaviors, or mortality, which indicated
that the median lethal dose (LD50) of PLE was higher than
5000 mg/kg body weight. The effective dose (500 mg/kg body
weight) was selected based on this proposed LD50.
Diagnostic markers of diabetic
Table 1 showed that serum glucose level and arginase activity
of both T1DM and T2DM rats were significantly increased
(p< 0.05), as compared to the corresponding control rats.
On the other hand, insulin concentration and liver G6PD
activity were decreased significantly (p< 0.05), as compared
to the corresponding ones of the control groups.
Treatment of T1DM and T2DM rats with PLE (500 mg/kg
body weight) significantly (p< 0.05), decreased glucose level
and arginase activity as well as increasing the insulin concen-
tration and liver G6PD activity as compared to the corre-
sponding ones of diabetic rats. It was evidenced from the %
of improvement calculation that PLE treatment showed high-
est amelioration regarding T1DM than those in T2DM
(Table 1).
Liver function markers
Induction of both types of diabetes caused a significant
increase (p< 0.05) in the activities of AST, ALT, ALP,
GGT, and levels of total and indirect bilirubin of rats except
for the AST of T2DM rats (non significantly changed), as com-
pared to the corresponding control ones (Tables 2 and 3). Sig-
nificant decrease (p< 0.05) was noticed in the levels of total
protein of both T1DM and T2DM rats, as compared to the
corresponding control ones (Table 3).
Serum activities of ALT and ALP of both diabetic rat mod-
els were significantly decreased (p< 0.05) after 15 days of PLE
treatment, as compared to the corresponding DM rats. More-
over, PLE treatment was found more effective to improve the
ALT and ALP activities of T1DM rats than T2DM rats
(Table 2). Meanwhile, PLE treatment significantly decreased
(p< 0.05) the AST activity of T1DM rats and GGT activity
of T2DM rats with% of improvement of 225.95 and
2634.73, respectively (Table 2). On the other hand, a signifi-
cant increase (p< 0.05) was shown in the total protein, total
and direct bilirubin levels of T1DM and T2DM rats and indi-
rect bilirubin of T2DM rats only after PLE administration for
15 days, as compared to the corresponding DM groups
(Table 3).
Lipid profile markers
Data represented in Table 4 showed that the serum levels of
total lipids, total cholesterol, and LDL-cholesterol of both
Table 1 The curative impact of Paracentrotus lividus extract (PLE) on the diabetic markers of the high fat diet/streptozotocin models
of diabetes in rats.
Diabetic markers Serum glucose (mg/dl) Serum insulin (lU/ml) Serum arginase (U/L) Liver G6PD (U/min/g protein)
T1DM
Control 89.83 ± 10.14a 17.00 ± 0.21d 106.67 ± 1.58a 1.15 ± 0.07c
DM model 368.67 ± 53.27c 3.10 ± 0.55a 195.67 ± 15.70d 0.36 ± 0.08a
PLE 138.67 ± 20.13ab 7.08 ± 0.51b 151.00 ± 16.11bc 0.66 ± 0.08b
% improvement 256.03 23.41 41.87 26.09
T2DM
Control 127.50 ± 6.00ab 18.00 ± 0.50d 117.17 ± 3.36a 1.55 ± 0.11d
DM model 315.67 ± 7.20c 5.99 ± 0.65b 163.33 ± 6.69c 0.21 ± 0.02a
PLE 180.33 ± 19.12b 9.67 ± 0.40c 124.67 ± 8.69ab 0.65 ± 0.16b
% improvement 106.14 20.44 32.99 28.39
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (p< 0.05). DM: diabetes mellitus, G6PD: glucose 6 phosphate
dehydrogenase, PLE: Paracentrotus lividus extract, T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus.
Table 2 The curative impact of Paracentrotus lividus extract (PLE) on some serum enzymes (liver function markers) of the high fat
diet/streptozotocin models of diabetes in rats.
Liver function markers s.AST (U/ml) s.ALT (U/ml) s.ALP (IU/L) s.GGT (U/L)
T1DM
Control 28.25 ± 1.58ab 14.17 ± 3.00a 88.33 ± 7.06ab 1.16 ± 0.14a
DM model 92.75 ± 18.17c 54.54 ± 6.73c 373.33 ± 11.77e 13.74 ± 0.57b
PLE 28.92 ± 2.15ab 21.83 ± 2.77a 178.33 ± 31.66d 5.32 ± 1.95ab
% improvement 225.95 230.84 220.76 702.59
T2DM
Control 20.17 ± 0.76ab 23.58 ± 1.36a 77.00 ± 13.74a 1.67 ± 0.21a
DM model 45.00 ± 1.00b 70.83 ± 4.98d 143.33 ± 6.48cd 46.33 ± 8.91c
PLE 27.63 ± 1.37ab 42.17 ± 1.88b 92.17 ± 13.84ab 2.33 ± 0.21a
% improvement 86.12 121.54 66.44 2634.73
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (p< 0.05). s.AST: serum aspartate aminotransaminase, s.ALT:
serum alanine aminotransaminase, s.ALP: serum alkaline phosphatase, s.GGT: serum gamma glutamyltransferase, DM: diabetes mellitus, PLE:
Paracentrotus lividus extract, T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus.
Table 3 The curative impact of Paracentrotus lividus extract (PLE) on some serum parameters (liver function markers) of the high fat
diet/streptozotocin models of diabetes in rats.
Serum parameters Total protein (g/dl) Total bilirubin (mg/dl) Direct bilirubin (mg/dl) Indirect bilirubin (mg/dl)
T1DM
Control 6.94 ± 0.75c 5.38 ± 0.34a 4.98 ± 0.19a 0.40 ± 0.16a
DM model 3.22 ± 0.27a 6.15 ± 0.12b 5.20 ± 0.42a 0.95 ± 0.20b
PLE 5.11 ± 0.64b 6.51 ± 0.06c 5.50 ± 0.11b 0.99 ± 0.27b
% improvement 27.23 6.69 6.02 10.00
T2DM
Control 6.00 ± 0.37b 5.65 ± 0.09a 5.53 ± 0.35a 0.12 ± 0.23a
DM model 3.17 ± 0.31a 6.22 ± 0.09b 5.62 ± 0.40a 0.60 ± 0.14b
PLE 5.67 ± 0.42bc 6.72 ± 0.12c 5.82 ± 0.10b 0.88 ± 0.19c
% improvement 41.67 8.85 3.61 233.33
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (p< 0.05). DM: diabetes mellitus, PLE: Paracentrotus lividus
extract, T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus.
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rats were significantly increased (p< 0.05). However, a signif-
icant decrease (p< 0.05) was noticed in the level of HDL-
cholesterol of both diabetic rat models, as compared to the
corresponding control rats.PLE treatment caused a significant decrease (p< 0.05) in
the levels of total cholesterol and LDL-cholesterol of both dia-
betic rat models and only the total lipids level of T1DM as well
as the concentration of triglycerides of T2DM rats, as com-
pared to the corresponding DM ones (Table 4). In addition,
Table 5 The curative impact of Paracentrotus lividus extract (PLE) on liver oxidative stress markers of the high fat diet/
streptozotocin models of diabetes in rats.
Oxidative stress markers MDA (nmol/g protein) GSH (mg/g protein) NO (lmol/L)
T1DM
Control 12.90 ± 1.37a 7.72 ± 0.64cd 37.83 ± 2.40d
DM model 25.47 ± 2.19c 3.12 ± 0.53a 22.33 ± 1.20a
PLE 22.77 ± 0.74bc 3.91 ± 0.67ab 28.83 ± 2.76bc
% improvement 20.93 10.23 17.18
T2DM
Control 20.00 ± 2.02b 11.33 ± 0.67e 32.33 ± 3.07bc
DM model 30.33 ± 2.01d 3.00 ± 0.77a 28.17 ± 0.31ab
PLE 23.17 ± 1.99bc 8.00 ± 0.37cd 26.67 ± 1.78ab
% improvement 35.80 44.13 4.64
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (p< 0.05). DM: diabetes mellitus, PLE: Paracentrotus lividus
extract, T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus, MDA: malondialdehyde, GSH: glutathione reduced, NO: nitric oxide.
Table 6 The curative impact of Paracentrotus lividus extract (PLE) on liver oxidative stress markers of the high fat diet/
streptozotocin models of diabetes in rats.
Oxidative stress markers GST (U/ g protein) GPs (U/g tissue) SOD (U/g protein) CAT (U/g protein)
T1DM
Control 3.57 ± 0.15cd 5.95 ± 0.90c 78.05 ± 3.16c 1.93 ± 0.02c
DM model 0.90 ± 0.23a 2.60 ± 0.55ab 47.96 ± 7.82b 1.61 ± 0.05a
PLE 2.93 ± 0.19c 5.70 ± 0.60c 69.73 ± 5.11c 1.77 ± 0.05ab
% improvement 56.86 52.10 27.89 8.29
T2DM
Control 3.97 ± 0.14d 6.13 ± 0.48c 71.17 ± 0.70c 1.86 ± 0.05bc
DM model 1.33 ± 0.40ab 1.33 ± 0.34a 17.00 ± 0.73a 1.68 ± 0.03ab
PLE 3.85 ± 0.63cd 4.36 ± 0.66ab 37.50 ± 4.14b 1.93 ± 0.04c
% improvement 63.48 49.43 28.80 13.44
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (p< 0.05). DM: Diabetes mellitus, PLE: Paracentrotus lividus
extract, T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus, GST: glutathione S transferase, GPs: glutathione peroxidase, SOD:
superoxide dismutase, CAT: catalase.
Table 4 The curative impact of Paracentrotus lividus extract (PLE) on some serum lipid profile markers of the high fat diet/
streptozotocin models of diabetes in rats.
Lipid profile Total lipids (mg/dl) Triglycerides (mg/dl) Total cholesterol (mg/dl) LDL-cholesterol (mg/dl) HDL-cholesterol (mg/dl)
T1DM
Control 143.17 ± 6.52a 129.00 ± 2.31a 165.67 ± 8.67a 131.67 ± 3.33ab 60.83 ± 2.20d
DM model 310.17 ± 28.17c 152.50 ± 4.72ab 227.17 ± 16.83b 190.50 ± 15.48c 44.41 ± 0.38a
PLE 109.00 ± 21.40a 142.33 ± 12.33ab 171.67 ± 6.90a 132.00 ± 9.36ab 54.35 ± 4.77bcd
% improvement 140.51 7.88 33.50 44.43 16.34
T2DM
Control 101.83 ± 15.85a 157.17 ± 9.66bc 168.83 ± 11.24a 120.67 ± 8.02a 60.04 ± 2.08d
DM model 249.50 ± 17.75b 230.50 ± 9.63e 211.50 ± 5.79b 153.67 ± 3.77b 47.23 ± 1.54abc
PLE 230.67 ± 9.28b 173.50 ± 1.73cd 174.50 ± 5.97a 125.33 ± 4.22a 55.32 ± 3.25cd
% improvement 18.49 36.27 21.92 23.49 13.47
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (p< 0.05). DM: Diabetes mellitus, PLE: Paracentrotus lividus
extract, T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus.
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cholesterol level of T1DM rats. PLE treatment was found to
cause the highest improvement in the total lipids level of
T1DM rats by 140.51%.Liver oxidative stress markers
Experimentally induced T1DM and T2DM caused a signifi-
cant increase (p< 0.05) in the level of liver MDA (Table 5).
14 A.M. SolimanHowever, a significant decrease (p< 0.05) was noticed in the
levels of liver GSH, GST, GPs, and SOD of both diabetic
rat models and the levels of liver NO and CAT of T1DM rats
only, as compared to the control ones (Tables 5 and 6).
Treatment the T2DM rats with PLE for 15 days signifi-
cantly decreased (p< 0.05) the MDA level with 35.80%
improvement. On the other hand, PLE treatment caused a sig-
nificant increase (p< 0.05) in the GST and SOD activities of
both diabetic rat models (56.86%, 63.48%, 27.89%, 28.80%
improvement, respectively), NO level and GPs activity of
T1DM rats (17.18, 52.10% improvement, respectively), and
GSH level and CAT activity of T2DM rats (44.13%, 13.44%
improvement, respectively), as compared to the corresponding
DM ones (Tables 5 and 6).Discussion
Diabetes induced by streptozotocin alters the structure and
function of the body including the liver cells (Chalfoun-
Mounayar et al., 2012). Diabetes mellitus (DM) is associated
with various structural and functional liver abnormalities,
including non-alcoholic fatty liver disease (NAFLD) and hep-
atic glycogenosis (HG). NAFLD represents the most common
liver disease associated with DM, especially in patients with
type 2 diabetes (T2DM) and metabolic syndrome (Krishnan
et al., 2013). Due to the high prevalence of diabetes worldwide,
extensive research is still being performed to develop new
antidiabetic agents and determine their mechanisms of action,
consequently, a number of diabetic animal models have been
developed and improved over the years (Islam and Loots,
2009). Although several synthetic antidiabetics are developed
but the safe and effective treatment paradigm is yet to be intro-
duced (Bhattacharjee et al., 2014).
The present experimental data showed that a high dose of
STZ (60 mg/kg body weight) and a high-fat diet plus low dose
of STZ (30 mg/kg body weight) administration can success-
fully induce T1DM and T2DM rat models, respectively. Type
1 and type 2 diabetes were established in the present study as
fasting glucose level increased and insulin level decreased
which may indicate impaired glucose tolerance (Bielohuby
et al., 2013). In both type 1 and type 2 diabetes, diabetic com-
plications in target organs arise from chronic elevations of glu-
cose (Evans et al., 2003).The significant decrease in serum
insulin concentration in the both diabetic rat models was due
to the cytotoxic effects of STZ through the induction of free
radicals that damaged the pancreatic b cells (Sakai et al.,
2003; Aydin and Celik, 2012). On the other hand, PLE admin-
istration remarkably attenuated the high blood sugar and
increased insulin levels. This ameliorative effect of the current
extract may be due to the presence of saponins (Kihara et al.,
1985). Saponins, compound with insulin-like properties, stim-
ulate glucose uptake enhancing Glut4 expression, contributing
to storage of glucose as glycogen in adipocytes (Elekofehinti
et al., 2014). In accord with the present results, O¨ztu¨rk et al.
(2015) investigated that some substances express anti-diabetic
property by influencing cells to stimulate insulin secretion
and restore insulin sensitivity.
Arginase is an intracellular enzyme that appears in the
plasma only after cell damage or death. The type 1 isoform
of arginase predominantly is located in the liver and kidney,
while the type 2 isoform is predominantly found in endothelialcells and can be induced in many cell types by a variety of
inflammatory cytokine factors (Morris, 2002). Thus, chronic,
low grade inflammation and liver disease are potential sources
of elevated arginase activity in type 2 diabetes. In line with the
previous investigation, there was an increase in the arginase
activity regarding type 2 DM as well as T1DM rat models in
the present study. Ramı´rez-Zamora et al. (2013) and Wei
et al. (2013) have inspected the prospective role of arginase
(including arginase I and II) in the pathogenesis of DM.
Wang et al. (2014a,b) investigated the potential role of argi-
nase I as a diagnostic or prognostic marker for type 2 DM.
They added that the diabetic rats exhibited increased levels
of arginase, which correlated with the blood glucose level
and may contribute to the severity of DM in rats.
Other curative patterns, including aggravating control of
hyperglycemia with insulin, should be assessed for their ability
to increase arginine bioavailability and inhibited arginase
activity (Kashyap et al., 2008). In the current study, adminis-
tration of PLE for 15 days for both T1DM and T2DM rats
caused a significant decrease in the arginase activity.
Sarikaphuti et al. (2013) stated that inhibition of arginase
has been shown to have a protective effect in DM rat models.
The adverse effect of diabetes mellitus on the liver is still
unknown (Orasanu and Plutzky, 2009). The increased activi-
ties of serum transaminase enzymes (AST, ALT), alkaline
phosphatase (ALP), gama glutamyl transferase (GGT) and
total bilirubin levels of both T1DM and T2DM, which were
used as markers of liver function, were found to be correlated
with the increased arginase activity in the current study. Hepa-
tocyte injury caused impairment in the liver cell membrane
permeability. As a result, cytoplasmic enzymes such as
transaminase (AST and ALT) leakage into the circulation
and their activities in serum increase (Arun and Nalini,
2002). In addition, ALP is membrane bound and its alteration
is likely to affect the membrane permeability and produce
derangement in the transport of metabolites (Mehana et al.,
2012). On the other hand, bilirubin value is associated with
the function of hepatic cells (Muriel et al., 1992). Bilirubin is
generated when the heme part of the hemoglobin has under-
gone degradation. This results in the formation of biliverdin,
which is rapidly converted into bilirubin. In hepatocytes,
unconjugated (lipid-soluble) bilirubin is conjugated by uridine
diphosphate–glucuronosyl transferase (UDP–GT) to a water-
soluble form for excretion. Total bilirubin is the sum of conju-
gated (direct) and unconjugated (indirect) bilirubin (Hull and
Agarwal, 2014). However, unconjugated bilirubin levels have
positive correlation with plasma antioxidant capacity, and
moderate rises in serum total bilirubin have been linked with
reduced capability to several common diseases (Vı´tek et al.,
2002).
Two studies, relating serum ALT content to type 1 diabetes,
found elevated levels of the enzyme in 10–35% of type 1 dia-
betes patients, respectively (West et al., 2006; Leeds et al.,
2009). Another study found that ALT, AST, ALP, GGT, and
bilirubin were used as indicators of NAFLD and they signifi-
cantly correlated with insulin resistance in type 1 diabetes
patients (Bulum et al., 2011). Furthermore, recognition of the
role of the liver in the pathogenesis of type 2 diabetes has been
increasing. Nonalcoholic fatty liver disease (NAFLD), charac-
terized by elevated ALT, and GGT is now regarded as the hep-
atic manifestation of the insulin resistance syndrome
(Marchesini and Forlani, 2002). Bell and Allbright (2007)
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increased in patients with either type 1 or type 2 diabetes.
The significant decrease of total protein level of diabetic
rats in the present study may be due to the anabolic effect of
insulin on protein metabolism as it stimulates protein synthesis
and retards protein degradation (Murray et al., 2000). Protein
synthesis is decreased in all tissues due to decreased ATP pro-
duction in response to absolute or relative deficiency of insulin
and alkaline phosphatase activity (Chatterjee and Rana, 1994).
Mahboob et al. (2005) investigated decreased protein content
of serum in diabetic patients indicating high rate of the lipid
peroxidation process and decreased the antioxidant defensive
system.
Treatment of both diabetic rat models with PLE caused a
reduction in the activity of the enzymes (AST, ALT, ALP,
GGT) and increased total protein level which may be due to
the ability of PLE to counteract lipid peroxidation and per-
haps heal the damaged cells (Akpan and Ekpo, 2015).
O¨ztu¨rk et al. (2015) results were in accord with the present
study. In the present study, PLE treatment caused an unex-
pected increase in levels of total, direct and indirect bilirubin
as compared to the corresponding diabetic rats. Vı´tek (2012)
reported that bilirubin has been recognized as a substance with
potent antioxidant properties. Although bilirubin was believed
to be only a waste product of the heme catabolic pathway at
best, and a potentially toxic compound at worst; recent data
have convincingly demonstrated that mildly elevated serum
bilirubin levels are strongly associated with a lower prevalence
of oxidative stress-mediated diseases (Vı´tek, 2012). Further-
more, Liu et al. (2015) proved that unconjugated bilirubin
mediates heme oxygenase-1 (HMOX1) which is a key antioxi-
dant enzyme that has consistently been shown to protect from
the development of diabetes (Ndisang, 2010). Therefore, the
increased level of bilirubin after PLE treatment may be due
to its enhancement effect on HMOX1 via bilirubin.
Glucose-6-phosphate dehydrogenase (G6PD) is the rate-
limiting enzyme of the pentose phosphate pathway (PPP).
The major products of the PPP are ribose-5-phosphate, which
is required for nucleic acid synthesis, and nicotinamide adenine
dinucleotide phosphate (NADPH) generated from NADP by
G6PD (Stanton, 2012). There has been a growing understand-
ing of the central importance of G6PD to cellular physiology
as it is a major source of NADPH that is required by many
essential cellular systems including the antioxidant pathways,
nitric oxide synthase, NADPH oxidase, cytochrome p450 sys-
tem, and others. Indeed G6PD is essential for cell survival,
since G6PD activity was found to be correlated directly with
cell growth. Inhibition of G6PD activity prevented cell growth,
and overexpression of G6PD alone stimulated cell growth
(Tian et al., 1998). In the present study, liver glucose-6-
phosphate dehydrogenase activity of both diabetic rat models
decreased significantly. This decrease in liver G6PD activity
was consistent with the decreased insulin levels in the current
study since; insulin is the key stimulating factor for G6PD
which aids in the utilization of glucose via pentose phosphate
pathway (Tian et al., 1998). Similarly, significant decreases in
G6PD activity were investigated due to hyperglycemia or dia-
betes in the liver, kidney, pancreas, and other tissues (Diaz-
Flores et al., 2006; Zhang et al., 2010). West (2002) proposed
that predisposition to diabetes may be due to alterations in
gene controlling both insulin secretion and G6PD-mediated
antioxidant defenses.The increased liver G6PD activity subsequent to PLE treat-
ment may be considered as an important therapeutic tactic for
the prevention and treatment of diabetic complications
(Stanton, 2012). It was concluded that increased G6PD activ-
ity was essential for preventing ROS-mediated cell death (Tian
et al., 1999).
The liver is an insulin – dependent tissue that plays a signif-
icant role in glucose and lipid homeostasis and is severely
affected in diabetes (O¨ztu¨rk et al., 2015). Hyperlipidaemia
has been reported to accompany hyperglycemia states
(Taskinen, 1996). In the present study diabetic rats (T1DM
and T2DM) showed high levels of total lipids, triglycerides
(TG), total cholesterol (TC), LDL-cholesterol and a lower
level of HDL-cholesterol. High levels of TC; importantly
LDL cholesterol is one of the major coronary risk factors
(Temme et al., 2002) which is the major cause of morbidity
and deaths in diabetic subjects (Baynes, 1991). Similar results
were previously reported (Gong et al., 2009; Lu et al., 2010).
In addition, Lambert et al. (2013) have proposed that diabetic
individuals have reduced synthesis and increased cholesterol
absorption. Furthermore, it was concluded that in patients
with reduced insulin secretion, the adipocytes may uncouple
the adipose tissue from circulating fatty acids so that fatty
acids are instead shunted to the liver, resulting in increased
synthesis of triglycerides (Nielsen et al., 2014). Ribas et al.
(2014) investigated that the increased total cholesterol could
result in depletion of mitochondrial glutathione concentrations
and oxidative stress.
P. lividus extract treatment to both T1DM and T2DM rats
caused alleviations to all the studied lipid profile parameters
and confirmed its hypolipidemic potency. This effect may be
attributed to the presence of saponins which inhibited choles-
terol and/or bile acid absorption (Elekofehinti et al., 2014).
The observed hypolipidemic effect of PLE seems to be inde-
pendent of insulin action and may be through the inhibition
of the key enzymes on cholesterol and triglyceride synthesis
(Zhang et al., 2002). Nevertheless, it cannot preclude the rela-
tion between the observed hypolipidemic effects and diabetes
since the major determinant of total cholesterol and triglyc-
eride is glycemic control (Dangi and Mishra, 2010).
Oxidative stress is referred to as a reactive oxygen species
(ROS)/antioxidant inequality, occurs when the net amount
of ROS exceeds the antioxidant potential. Thus, oxidative
stress can occur because of a general increase in ROS genera-
tion, a drooping of the antioxidant systems, or both (France´s
et al., 2013). It is well established that hyperglycemia excavates
an increase in ROS production, which leads to oxidative stress
in both type 1 and type 2 diabetes and causes antioxidant
defense enzymes and vitamin deficiency (West, 2000).
France´s et al. (2010) demonstrated that hyperglycemia
increases the hydroxyl radical production in the liver of
STZ-induced diabetic rats. In the present study, elevated
malondialdehyde (MDA, end product of lipid peroxidation),
decreased glutathione reduced (GSH) and nitric oxide (NO),
and the inhibition of the antioxidant enzyme activities (glu-
tathione S transferase (GST), glutathione peroxidase (GPs),
superoxide dismutase (SOD), catalase (CAT)) are evidence of
oxidative stress occurrence in the diabetic untreated rats.
Increased levels of liver MDA in diabetics suggest that per-
oxidative injury may be involved in the development of liver
damage (Srivastava et al., 2001). This marked increase in the
lipid peroxidation rates in diabetic liver tissues suggests an
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either increased production and/or decreased elimination
(Sadi et al., 2013). GSH has free radical scavenging activity
and it is involved in the removal of reactive intermediates in
the presence of GPx and GSTs. Previous studies have shown
that, hepatic GSH concentration of STZ induced diabetic rats
significantly decreased (Maritim et al., 2003; Pari and Latha,
2005). NO has been stated to modulate insulin sensitivity
and glucose disposal (Kapur et al., 1997), and its activity has
been shown to be impaired by hyperglycemia and insulin resis-
tance (Roy et al., 1998). The aforementioned data in the pre-
sent study revealed that diabetic rats have increased arginase
activity which converts L-arginine to urea and ornithine. Since,
under conditions of low arginine levels which is the nitric oxide
synthase (NOS) substrate, NOS is uncoupled, producing reac-
tive oxygen species and oxidative stress instead of NO (Xia
et al., 1996). Furthermore, insulin resistance in type 2 diabetes
may contribute to reduced NOS activity by the generation of
methylated arginine (Kashyap et al., 2008). The observed inhi-
bition in the liver antioxidant enzyme activities (GST, GPx,
SOD, CAT) in the current study may be due to down regula-
tion of their expression genes that resulted from the excessive
oxidative stress that occurred in the liver due to diabetes
(Raza et al., 2000; Sadi et al., 2008).
Inhibition of oxidative stress with antioxidants might be
potent for alleviating the complications of diabetes. Several
investigators showed the beneficial effects of antioxidants in
the treatment of diabetes (Maritim et al., 2003; Sadi and
Guray, 2009). The present study revealed that PLE treatment
of diabetic rats (T1DM and T2DM) ameliorated the lipid per-
oxidation, which was assessed by the decreased liver MDA
level, most probably by decreasing the cellular redox potential
(Sadi et al., 2013). Moreover, PLE caused increased levels of
liver GSH, NO, and antioxidant enzyme activity (GST,
GPx, SOD, CAT) of diabetic rats. These results could confirm
the antioxidant potency of PLE which was attributed to the
presence of a biologically active pigment known as echino-
chrome A, a polyhydroxy naphthoquinone isolated from the
sea urchin that has antioxidant properties (Lebedev et al.,
2005). Many in vivo and in vitro studies have shown that treat-
ments targeting oxidative stress improve both b-cell function
and survival (Wajchenberg, 2007). It has been found that
using different antioxidants improve insulin sensitivity in
experiments using animal models of diabetes or in vitro studies
(Rudich et al., 1999; Maddux et al., 2001). Indeed, PLE and its
content from the echinochrome pigment may be able to cor-
rect the deficient thiol status of cells by increasing de novo syn-
thesis of GSH and hence increased the liver GSH levels in
diabetic animals (Han et al., 1997). Interestingly, since
G6PD is the main source of NADPH used by the cellular
antioxidant systems, it can be inferred that the enhanced
G6PD (aforementioned results) would have a highly benefi-
cial, protective effect by increasing CAT, GPx and SOD activ-
ities, as the handling of hydrogen peroxide by either catalase
or the glutathione system will involve in cellular defense
against a wide variety of free radicals (Medina and Moreno-
Otero, 2005; Zhang et al., 2010). In addition, several investiga-
tors showed that overexpression of antioxidants as GPx and
CAT could protect islets against oxidative stress and provide
protection against the deleterious effects of hyperglycemia
(Benhamou et al., 1998; Tanaka et al., 2002; Moriscot et al.,
2003).Conclusion
P. lividus extract (PLE) was safe and able to protect diabetic
oxidative stress and liver damage because it is rich in diverse
antioxidants. The present study confirms that PLE exerted a
hypoglycemic effect and improved the lipid profile. PLE effi-
ciency in treating T1DM and T2DM was variable and depend-
ing on the estimated parameters. Furthermore, PLE may be
useful as therapy against oxidative stress and liver damage in
both types of diabetes mellitus and is therefore recommended
for further studies. These effects should be studied further in
human volunteers and diabetic patients.
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